News >

Brigatinib Elicits Responses in ALK+ NSCLC Following Next-Generation TKIs

Lisa Astor
Published: Friday, Jun 07, 2019

Thomas E. Stinchcombe, MD

Thomas E. Stinchcombe, MD

Brigatinib (Alunbrig) demonstrated promising response rates in patients with ALK-positive non–small cell lung cancer (NSCLC) who have progressed on treatment with another next-generation ALK TKI, according to preliminary phase II results presented at the 2019 ASCO Annual Meeting.1

 
References
  1. Stinchcombe T, Doebele RC, Wang XF, et al. Preliminary results of single arm phase 2 trial of brigatinib in patients (pts) with progression disease (PD) after next-generation (NG) Anaplastic Lymphoma Kinase (ALK) tyrosine kinase inhibitors (TKIs) in ALK + non-small cell lung cancer (NSCLC). J Clin Oncol. 2019;37(suppl; abstr 9027). meetinglibrary.asco.org/record/174623/abstract.
  2. Kim DW, Tiseo M, Ahn MJ, et al. Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial. J Clin Oncol. 2017;35(2:2490-2498. doi: 10.1200/JCO.2016.71.5904.
  3. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer. N Engl J Med. 2018;379(21):2027-2039. doi: 10.1056/NEJMoa1810171.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Practical Application of Sequencing for EGFR-Mutant Lung Cancers: A Focus on Recent Evidence and Key Next Steps in TrialsJun 29, 20192.5
Community Practice Connections™: 3rd Annual School of Gastrointestinal Oncology® (SOGO®)Jun 29, 20191.5
Publication Bottom Border
Border Publication
x